Skip to main content
. 2024 Oct 29;19(10):e0309896. doi: 10.1371/journal.pone.0309896

Table 1. Baseline clinical and metabolic characteristics of population group and groups with prediabetes.

Total n = 1431 No glucose metabolism disturbances n = 634 Mean (95% CI) Population with prediabetes n = 797
IFG n = 415 Mean (95% CI) IGT n = 298 Mean (95% CI) Population with prediabetes based on HbA1c alone n = 84 Mean (95% CI)
Age, years 46.82 (46.05–47.59) 39.60 (38.62–40.57) 50.15 (48.83–51.46) 55.46 (53.87–57.05) 54.23 (50.99–57.47)
Sex, male, n, % 52.8% (43.4%-62.1%) 38.8% (35.1%-42.7%) 57.8% (53.0%-62.5%) 45.3% (39.7%-51.0%) 26.2% (18.0%-36.5%)
BMI, kg/m2 26.30 (26.06–26.54) 24.70 (24.39–25.02) 27.48 (27.06–27.90) 28.21 (27.67–28.76) 25.78 (24.85–26.71)
WHR 0.86 (0.85–0.86) 0.83 (0.82–0.83) 0.89 (0.88–0.90) 0.89 (0.88–0.90) 0.84 (0.83–0.86)
SBP mmHg 122.18 (121.31–123.04) 116.63 (115.51–117.76) 126.91 (125.33–128.49) 128.03 (125.97–130.08) 119.93 (116.81–123.06)
DBP mmHg 80.48 (79.96–80.99) 78.04 (77.36–78.72) 82.79 (81.82–83.77) 82.98 (81.76–84.20) 78.60 (76.44–80.77)
Total cholesterol, mg/dl, 193.63 (191.59–195.67) 185.15 (182.46–187.84) 202.46 (198.47–206.45) 195.97 (191.36–200.58) 205.70 (196.20–215.21)
Triglycerides, mg/dl 109.45 (105.34–113.56) 96.59 (89.84–103.34) 116.00 (109.74–122.25) 128.71 (119.21–138.21) 105.86 (95.64–116.08)
HDL-C, mg/dl, 62.17 (61.31–63.03) 63.83 (62.58–65.09) 60.91 (59.23–62.59) 59.47 (57.72–61.21) 65.42 (61.63–69.21)
LDL-C, mg/dl, 123.86 (122.00–125.72) 115.68 (113.23–118.13) 132.76 (129.14–136.38) 126.15 (122.03–130.26) 133.36 (124.28–142.45)
Cholesterol-lowering treatment, % 25.5% (18.1%-34.5%) 2.7% (1.7%-4.3%) 10.8% (8.2%-14.2%) 20.5% (16.3%-25.4%) 17.9% (11.1%-27.4%)
Fasting glucose level, mg/dl 97.87 (97.38–98.36) 90.78 (90.34–91.22) 105.77 (105.25–106.28) 103.40 (102.38–104.41) 92.70 (91.60–93.80)
Serum glucose concentration, 1h after glucose loading, mg/dl 143.57 (141.33–145.82) 120.85 (118.29–123.40) 152.38 (148.91–155.85) 178.48 (173.99–182.97) 133.75 (124.61–142.89)
Serum glucose concentration, 2h of glucose loading, mg/dl, 117.70 (116.24–119.17) 102.43 (100.99–103.87) 112.54 (110.70–114.37) 158.98 (157.20–160.75) 112.08 (107.88–116.29)
Fasting insulin concentration, mg/dl, 11.81 (11.41–12.21) 9.63 (9.23–10.04) 13.45 (12.71–14.20) 14.92 (13.71–16.14) 9.94 (8.96–10.91)
Serum insulin concentration, 1h after glucose loading, mg/dl, 84.87 (81.09–88.65) 66.26 (62.43–70.09) 98.36 (90.74–105.98) 105.73 (95.33–116.12) 77.68 (66.20–89.16)
Serum insulin concentration, 2h after glucose loading, mg/dl, 61.99 (58.78–65.21) 43.38 (40.99–45.77) 56.55 (52.03–61.07) 110.48 (99.53–121.42) 55.82 (47.75–63.88)
HbA1c, % 5.36 (5.34–5.38) 5.16 (5.14–5.18) 5.45 (5.42–5.48) 5.51 (5.47–5.55) 5.84 (5.81–5.86)
HOMA-IR 2.90 (2.80–3.01) 2.17 (2.08–2.27) 3.52 (3.32–3.72) 3.87 (3.54–4.20) 2.29 (2.06–2.52)
QUICKI 0.34 (0.33–0.34) 0.35 (0.35–0.35) 0.32 (0.32–0.33) 0.32 (0.32–0.33) 0.34 (0.34–0.35)
Matsuda Index 4.69 (4.52–4.85) 6.04 (5.77–6.31) 3.79 (3.57–4.01) 3.05 (2.82–3.28) 5.29 (4.46–6.12)
Average CCA IMT 0.63 (0.62–0.64) 0.58 (0.57–0.59) 0.65 (0.64–0.66) 0.70 (0.68–0.71) 0.67 (0.64–0.69)
Presence of any atherosclerotic plaques 70.8% (61.5%-78.6%) 23.3% (20.2%-26.8%) 50.4% (45.6%-55.1%) 61.4% (55.8%-66.8%) 50.0% (39.5%-60.5%)
Brachial- Ankle PWV, m/s 10.36 (10.24–10.49) 9.58 (9.42–9.74) 10.72 (10.51–10.93) 11.30 (11.03–11.57) 10.72 (9.95–11.50)
AIx 14.71 (14.06–15.36) 12.20 (11.28–13.11) 15.40 (14.20–16.60) 17.86 (16.51–19.20) 18.22 (14.88–21.56)

BMI–Body Mass Index, WHR–Waist-Hip Ratio, SBP–systolic blood pressure, DBP–diastolic blood pressure, HbA1c –glycated hemoglobin A1c, LDL -low density lipoprotein, HDL–high density lipoprotein, HOMA-IR—Homeostasis Model Assessment of Insulin Resistance, QUICKI- quantitative insulin sensitivity check index, CCA IMT—Carotid Artery Intima Media Thickness, PWV–pulse wave velocity, Aix- augmentation index, CI–Confidence interval.